Plumbagin has been reported to have anticancer and antiproliferative properties in various cancer cell lines and radio-sensitizing effects in cell culture models, in vitro, and mouse tumor models in vivo, including Ehrlich melanoma cells. A randomized double-blind study using a plant-based formulation containing plumbagin as an active component showed positive results in the management of chronic obstructive pulmonary disease in humans. Plumbagin is a plant-based secondary metabolite belonging to 1,4-napthoquinone class of quinones, exhibiting highly potent biological activities, including antioxidant, antiinflammatory, anticancer, antibacterial, and antifungal activities.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Plumbagin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.